Biogen and Japan’s Eisai said they had “positive” results from a midstage study of an experimental Alzheimer’s drug, offering signs a medicine could finally disrupt the disease’s memory-robbing course, though experts said it was too soon to say the drug marks a real advance.
from WSJ.com: US Business https://ift.tt/2KOHPgh
via IFTTT
No comments:
Post a Comment